Ages2Come
Menu
View all results →
Categories
⚡ Breaking
Australia posts second-quarter growth of 2.1%, beating expectations Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group Massachusetts’ 80-year-old senator sees off primary challenge over his age Pentagon chaos deepens after Driscoll quits in clash with Hegseth Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate Apple Maps changes Lake Ontario to Lake America after Trump order Larry Page’s flying car company Pivotal loses its CEO Bill Simmons’s Co-Hosts Are Tired of His A.I. Antics SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says Australia posts second-quarter growth of 2.1%, beating expectations Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group Massachusetts’ 80-year-old senator sees off primary challenge over his age Pentagon chaos deepens after Driscoll quits in clash with Hegseth Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate Apple Maps changes Lake Ontario to Lake America after Trump order Larry Page’s flying car company Pivotal loses its CEO Bill Simmons’s Co-Hosts Are Tired of His A.I. Antics SEC proposes transfer agent rule, sets event to figure out round-the-clock U.S. trading China dissented from G20 statement opposing 'cheap exports' flooding market, Bessent says
Programming / Mobile

AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers

Source: bloombergMarkets June 22, 2026 · 08:08
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO. (Source: Bloomberg)
Read original article ← Back to Mobile

The original article opens on the publisher's website.

More from Mobile

View topic →